BoltzMol-1 finds hits on WRN target that resisted 350,000 screened compounds
GabriCorso · x · 2026-09-16
Boltz published a real-world hit discovery case study for BoltzMol-1, targeting Werner helicase (WRN) — a synthetic-lethal dependency in MSI-H tumors common in colorectal, gastrointestinal and endometrial cancers.
Key points:
- WRN is an attractive test case: MSI-H tumor cells are 'addicted' to WRN for resolving stalled replication structures, so inhibiting it kills them while healthy cells tolerate its loss.
- The study asks whether the new model can surface novel chemical starting points on real drug-discovery targets with modest compute budgets and short timelines, rather than just recovering known binding modes.
- Benchmark comparison: Novartis needed three screening campaigns covering nearly 350,000 compounds to find its initial WRN hit — an effort the team estimates took months and cost at least an order of magnitude more.
- BoltzMol-1 is now available in Boltz Lab for researchers to run against their own targets.
Related event: BoltzMol-1 finds WRN inhibitors in ten days for under $10K(2 posts)→
More from Apps
- Anthropic merges Claude Cowork and chat into one Claude for Pro and Max — daniel_mac8 · 2026-09-17
- Anthropic engineer: merged Claude rolls out to Pro and Max in coming weeks — felixrieseberg · 2026-09-17
- Anthropic merges Claude Cowork into chat, launches Docs and Slides in beta — claudeai · 2026-09-17
- Claude can now generate decks, docs, and designs inside one conversation — claudeai · 2026-09-17
- Claude adds human-in-the-loop editing: fix docs, comment on slides, share via link — claudeai · 2026-09-17
- Anthropic merges Claude Cowork and chat into one Claude that works after you log off — claudeai · 2026-09-17